Cited 3 times in
Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이관식 | - |
dc.contributor.author | 이정일 | - |
dc.contributor.author | 이현웅 | - |
dc.contributor.author | 김자경 | - |
dc.contributor.author | 이익재 | - |
dc.contributor.author | 김준원 | - |
dc.contributor.author | 조연아 | - |
dc.contributor.author | 이광훈 | - |
dc.contributor.author | 주승문 | - |
dc.contributor.author | 임진홍 | - |
dc.date.accessioned | 2020-09-28T12:14:35Z | - |
dc.date.available | 2020-09-28T12:14:35Z | - |
dc.date.issued | 2020-06 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/179357 | - |
dc.description.abstract | Concurrent intra-arterial chemotherapy and radiotherapy (iA-CCRT) can increase the response rate in hepatocellular carcinoma (HCC), but may cause a higher toxicity. We conducted this Phase I study to investigate the dose-limiting toxicity of iA-CCRT for HCC. In total, 52.5 Gy in 25 fractions was prescribed as planning target volume (PTV) 1 at dose level 1. The dose escalation was 0.2 Gy per fraction and up to 2.5 Gy, with 62.5 Gy at level 3. Concurrent intra-arterial 5-fluorouracil was administered during the first and fifth weeks of radiotherapy (RT). Toxicities were graded using the Common Toxicity Criteria for Adverse Events, version 4.0. Results: Seventeen patients with HCC were analyzed: four at dose level 1, 6 at level 2, and 7 at level 3. The mean irradiated dose administered to the uninvolved liver at each dose level was 21.3, 21.6, and 18.2 Gy, respectively. There was no grade ≥3 gastrointestinal toxicity; two patients experienced grade 3 hyperbilirubinemia. All patients had Child-Pugh class A disease, but 3 patients developed class B disease after iA-CCRT. During a median follow-up of 13 months, the median progression-free survival (PFS) and overall survival (OS) were 10 and 22 months, respectively. Patients treated at dose level 3 showed improved PFS and OS. Conclusions: Radiation dose escalation of iA-CCRT did not cause any significant toxicities in patients with advanced HCC. Further large-scale studies with long-term follow-up are needed to determine the efficacy and feasibility of higher doses of iA-CCRT. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | CANCERS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yeona Cho | - |
dc.contributor.googleauthor | Jun Won Kim | - |
dc.contributor.googleauthor | Ja Kyung Kim | - |
dc.contributor.googleauthor | Kwan Sik Lee | - |
dc.contributor.googleauthor | Jung Il Lee | - |
dc.contributor.googleauthor | Hyun Woong Lee | - |
dc.contributor.googleauthor | Kwang-Hun Lee | - |
dc.contributor.googleauthor | Seung-Moon Joo | - |
dc.contributor.googleauthor | Jin Hong Lim | - |
dc.contributor.googleauthor | Ik Jae Lee | - |
dc.identifier.doi | 10.3390/cancers12061612 | - |
dc.contributor.localId | A02666 | - |
dc.contributor.localId | A03122 | - |
dc.contributor.localId | A03292 | - |
dc.contributor.localId | A00852 | - |
dc.contributor.localId | A03055 | - |
dc.contributor.localId | A00958 | - |
dc.contributor.localId | A04680 | - |
dc.contributor.localId | A02676 | - |
dc.contributor.localId | A05043 | - |
dc.contributor.localId | A03411 | - |
dc.relation.journalcode | J03449 | - |
dc.identifier.eissn | 2072-6694 | - |
dc.identifier.pmid | 32570869 | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | chemoradiotherapy | - |
dc.subject.keyword | radiotherapy | - |
dc.subject.keyword | toxicity | - |
dc.contributor.alternativeName | Lee, Kwan Sik | - |
dc.contributor.affiliatedAuthor | 이관식 | - |
dc.contributor.affiliatedAuthor | 이정일 | - |
dc.contributor.affiliatedAuthor | 이현웅 | - |
dc.contributor.affiliatedAuthor | 김자경 | - |
dc.contributor.affiliatedAuthor | 이익재 | - |
dc.contributor.affiliatedAuthor | 김준원 | - |
dc.contributor.affiliatedAuthor | 조연아 | - |
dc.contributor.affiliatedAuthor | 이광훈 | - |
dc.contributor.affiliatedAuthor | 주승문 | - |
dc.contributor.affiliatedAuthor | 임진홍 | - |
dc.citation.volume | 12 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1612 | - |
dc.identifier.bibliographicCitation | CANCERS, Vol.12(6) : 1612, 2020-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.